SymBio Pharmaceuticals (TSE:4582) Cyclically Adjusted Revenue per Share: 円181.84 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4582 SymBio Pharmaceuticals Ltd TSE:4582
36 GF Score
Price 円69.00
GF Value 円60.38
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is SymBio Pharmaceuticals Cyclically Adjusted Revenue per Share?

SymBio Pharmaceuticals TSE:4582 -1.43% 36 Cyclically Adjusted Revenue per Share is 円181.84 as of Dec. 2025. GuruFocus rates TSE:4582 with a GF Score™ of 36/100 and a GF Value™ of 円60.38 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

SymBio Pharmaceuticals's adjusted revenue per share for the three months ended in Dec. 2025 was 円5.663. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円181.84 for the trailing ten years ended in Dec. 2025.

During the past 12 months, SymBio Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was -10.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -7.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -26.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of SymBio Pharmaceuticals was -5.10% per year. The lowest was -47.90% per year. And the median was -26.90% per year.

As of today (2026-07-27), SymBio Pharmaceuticals's current stock price is 円69.00. SymBio Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was 円181.84. SymBio Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 0.38.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of SymBio Pharmaceuticals was 9.30. The lowest was 0.16. And the median was 0.94.


SymBio Pharmaceuticals  (TSE:4582) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

SymBio Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=69.00/181.84
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of SymBio Pharmaceuticals was 9.30. The lowest was 0.16. And the median was 0.94.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


SymBio Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


SymBio Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for SymBio Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SymBio Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

SymBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 237.01 227.11 217.41 202.51 181.84

SymBio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 198.08 191.98 188.14 181.84 0.00

TSE:4582 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, SymBio Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SymBio Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SymBio Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where SymBio Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


TSE:4582
36GF Score
SymBio Pharmaceuticals Ltd TSE:4582
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SymBio Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SymBio Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=5.663/113.0000*113.0000
=5.663

Current CPI (Dec. 2025) = 113.0000.

SymBio Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 23.856 97.900 27.536
201606 98.790 98.100 113.795
201609 17.323 98.000 19.974
201612 82.567 98.400 94.818
201703 72.323 98.100 83.308
201706 74.832 98.500 85.848
201709 49.777 98.800 56.931
201712 76.050 99.400 86.455
201803 62.092 99.200 70.730
201806 66.728 99.200 76.011
201809 57.601 99.900 65.154
201812 38.989 99.700 44.190
201903 78.154 99.700 88.580
201906 16.152 99.800 18.288
201909 0.126 100.100 0.142
201912 31.410 100.500 35.317
202003 19.917 100.300 22.439
202006 23.018 99.900 26.036
202009 27.613 99.900 31.234
202012 17.144 99.300 19.509
202103 37.198 99.900 42.076
202106 44.952 99.500 51.051
202109 62.642 100.100 70.715
202112 69.590 100.100 78.558
202203 59.330 101.100 66.313
202206 65.216 101.800 72.391
202209 61.871 103.100 67.812
202212 66.190 104.100 71.849
202303 39.080 104.400 42.299
202306 41.098 105.200 44.145
202309 31.240 106.200 33.240
202312 27.699 106.800 29.307
202403 13.866 107.200 14.616
202406 14.984 108.200 15.649
202409 13.393 108.900 13.897
202412 12.098 110.700 12.349
202503 5.584 111.100 5.679
202506 7.850 111.700 7.941
202509 6.535 112.000 6.593
202512 5.663 113.000 5.663

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円181.84 mean?
SymBio Pharmaceuticals (TSE:4582) has a Cyclically Adjusted Revenue per Share of 円181.84 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on SymBio Pharmaceuticals and its competitors.
Is SymBio Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
SymBio Pharmaceuticals' current Cyclically Adjusted Revenue per Share is 円181.84. Overall, SymBio Pharmaceuticals has a GF Score™ of 36/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS?
SymBio Pharmaceuticals' Cyclically Adjusted Revenue per Share of 円181.84 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on SymBio Pharmaceuticals and its competitors. SymBio Pharmaceuticals's current Cyclically Adjusted Revenue per Share is 円181.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, SymBio Pharmaceuticals (TSE:4582) is currently considered Modestly Overvalued. The stock's GF Value™ is 円60.38, compared to a current price of 円69.00 — trading 14.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円181.84. SymBio Pharmaceuticals' overall GF Score™ is 36/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For SymBio Pharmaceuticals (TSE:4582), the current Cyclically Adjusted Revenue per Share is 円181.84 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SymBio Pharmaceuticals (TSE:4582) Overvalued in 2026?

Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued. The current stock price of 円69.00 is trading 14.3% above its estimated GF Value™ of 円60.38. GuruFocus considers SymBio Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for TSE:4582:

  • Cyclically Adjusted Revenue per Share: 円181.84
  • GF Value™: 円60.38 vs. price of 円69.00 (14.3% above fair value)
  • GF Score™: 36/100 with 6 warning signs

No single metric tells the full story. See the TSE:4582 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SymBio Pharmaceuticals Business Description

Address 1-28 Toranomon 4-chome, 7th Floor, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
36GF Score

Get the complete analysis for TSE:4582

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円69.00
Price
円60.38
GF Value